Aptahem AB (publ) (NGM:APTA)

Market Cap	19.46M
Revenue (ttm)	2.47M
Net Income (ttm)	-7.64M
Shares Out	20.97M
EPS (ttm)	-0.36
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	74,631
Average Volume	21,963
Open	0.9640
Previous Close	0.9680
Day's Range	0.7020 - 0.9640
52-Week Range	0.5600 - 2.4000
Beta	0.46
RSI	44.43
Earnings Date	Nov 28, 2025

About Aptahem AB

Aptahem AB (publ), a biotechnology company, develops and sells aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions. The company’s lead products candidate is Apta-1, which is in preclinical stage to prevent the onset of life-threatening organ and tissue damage in sepsis patients. It has collaborations with various academic groups, including Consortium with Orebro University, Seattle Children’s Research Institute, and University Health Network. Aptahem AB (publ) was incorporated in 2014 and is based in Malmö, Swed...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 4
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: APTA

Financial Performance

In 2024, Aptahem AB's revenue was 3.77 million, a decrease of -63.95% compared to the previous year's 10.46 million. Losses were -8.57 million, -22.90% less than in 2023.